Actively Recruiting
Digital Health Support to Manage Symptoms and Side Effects in Adults with Advanced or Metastatic Sarcoma
Led by CareAcross · Updated on 2026-06-11
108
Participants Needed
11
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with locally advanced or metastatic sarcoma to understand how a personalized web-based platform can help improve quality of life by managing symptoms and side effects. This interventional study evaluates the impact of digital health support in addition to standard clinical treatments. The goal is to assess the effectiveness of personalized educational and supportive material delivered through the platform compared to simple reporting of symptoms. Participants are randomly assigned to one of two groups. One group uses the digital platform to report side effects but only receives acknowledgment of their submissions while continuing their standard care. The other group uses the platform to report side effects and also receives personalized educational and supportive content online. Both groups continue their usual clinical treatments such as surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, or hormonal therapy. Throughout the approximately one-year study period, participants provide patient-reported outcomes on symptoms and side effects via the platform. Researchers will measure side effect improvement from enrollment until completion and evaluate overall survival and patient satisfaction at the studys end. Monitoring occurs alongside standard care, and participation involves regular digital reporting and use of the online platform to support symptom management.
CONDITIONS
Brief Title
Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here